MedTrace Logo

Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study

NCT03134573 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2019-03-26

No results posted yet for this study

Summary

The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness tracker in the myBETAapp will be observed for 3 months.

Conditions

Interventions

DRUG

Interferon beta-1b (Betaferon, BAY86-5046)

Solution for injection

DEVICE

Betaconnect auto-injector

Auto-injector for application of Betaferon solution which automatically covers injection related data

DEVICE

myBETAapp

Medical device which can be connected with Betaconnect auto-injector and displays injection related data to patients and offers tracking of patient reported data at the wellness- tracker

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-15
Primary Completion
2018-05-09
Completion
2018-05-09

Countries

  • Germany

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03134573 on ClinicalTrials.gov